JP2016504315A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504315A5
JP2016504315A5 JP2015547441A JP2015547441A JP2016504315A5 JP 2016504315 A5 JP2016504315 A5 JP 2016504315A5 JP 2015547441 A JP2015547441 A JP 2015547441A JP 2015547441 A JP2015547441 A JP 2015547441A JP 2016504315 A5 JP2016504315 A5 JP 2016504315A5
Authority
JP
Japan
Prior art keywords
dengue
immunogenic composition
combination
virus
trivalent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015547441A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016504315A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/073757 external-priority patent/WO2014093182A1/en
Publication of JP2016504315A publication Critical patent/JP2016504315A/ja
Publication of JP2016504315A5 publication Critical patent/JP2016504315A5/ja
Pending legal-status Critical Current

Links

JP2015547441A 2012-12-14 2013-12-07 三価デングウイルス製剤に関する組成物、投与方法および使用 Pending JP2016504315A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737679P 2012-12-14 2012-12-14
US61/737,679 2012-12-14
PCT/US2013/073757 WO2014093182A1 (en) 2012-12-14 2013-12-07 Compositions, methods of administration and uses for trivalent dengue virus formulations

Publications (2)

Publication Number Publication Date
JP2016504315A JP2016504315A (ja) 2016-02-12
JP2016504315A5 true JP2016504315A5 (https=) 2017-01-26

Family

ID=50934851

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015547441A Pending JP2016504315A (ja) 2012-12-14 2013-12-07 三価デングウイルス製剤に関する組成物、投与方法および使用

Country Status (5)

Country Link
US (2) US9878031B2 (https=)
EP (1) EP2931310A4 (https=)
JP (1) JP2016504315A (https=)
CA (1) CA2933472A1 (https=)
WO (1) WO2014093182A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231581T1 (hr) 2013-03-15 2024-03-15 Takeda Vaccines, Inc. Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima
WO2016130786A2 (en) * 2015-02-15 2016-08-18 Integral Molecular, Inc. Flaviviridae proteins and virions and methods of use thereof
US11007261B2 (en) * 2016-04-13 2021-05-18 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
WO2020051334A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
MX2022001742A (es) * 2019-08-16 2022-04-07 Takeda Vaccines Inc Metodos para prevenir el dengue y la hepatitis a.
EP4375381B1 (en) * 2022-11-18 2026-02-25 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated dengue virus having a nucleotide sequence comprising at least one attenuation locus in a formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3000477A1 (en) 2000-02-16 2016-03-30 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Avirulent, immunogenic flavivirus chimeras
US20040120964A1 (en) 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
US20040259224A1 (en) 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
JP4993301B2 (ja) 2004-10-20 2012-08-08 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン
CN101238144B (zh) * 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
BRPI0613287A2 (pt) 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna
US20080193477A1 (en) * 2005-08-10 2008-08-14 Acambis Inc. Vaccination Against Dengue Virus Infection
DK2589602T3 (en) 2006-08-15 2016-07-25 The Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Development of dengue virus vaccine components
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
US20100316670A1 (en) 2007-06-14 2010-12-16 Blaney Joseph E Chimeric sle/dengue type 4 antigenic viruses
WO2010085358A2 (en) 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
NZ597000A (en) * 2009-06-01 2014-07-25 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
US20120294889A1 (en) 2010-11-12 2012-11-22 Paxvax, Inc. Chimeric Flavivirus Vaccines
NZ630831A (en) * 2012-06-10 2019-02-22 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus

Similar Documents

Publication Publication Date Title
JP2016504315A5 (https=)
JP2013542224A5 (https=)
JP2019151636A5 (https=)
JP2015535302A (ja) ビリオン分解に影響を及ぼすフラビウイルスのエンベロープタンパク質変異
KR20130138789A (ko) 재조합 서브유닛 뎅기 바이러스 백신
AU2017250696A1 (en) Compositions and methods of vaccination against dengue virus in children and young adults
NZ597000A (en) Compositions and methods for administration of vaccines against dengue virus
JP2017526689A5 (https=)
EP3474891B1 (en) Vaccine compositions comprising an attenuated mutant zika virus
Sim et al. Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen
WO2017156511A8 (en) Live attenuated zika virus vaccine
US9861692B2 (en) Dengue virus vaccine compositions and methods of use thereof
WO2014210358A1 (en) Methods and compositions for dengue virus vaccines
EP3236997B1 (en) Dengue virus vaccine compositions and methods of use thereof
EP3481848B1 (en) Genomic sequences encoding for an attenuated mutant zika virus
Roberts et al. New opportunities for control of dengue virus
JP5657204B2 (ja) デングウイルスのカプシドタンパク質を有する、デングウイルスに対する防御反応を誘導することができる医薬品組成物
ES2551699T3 (es) Composiciones, procedimientos y kits
CN103352047B (zh) 旋毛虫肌幼虫es抗原基因疫苗及其制备方法
Li et al. Comparison of the efficacy and safety of different immunization routes induced by human respiratory syncytial virus F protein with CpG adjuvant in mice
JP2014524450A5 (https=)
López et al. New evidence on the virus capsid as a vaccine candidate against the Dengue 2 virus without the induction of the neutralizing antibodies
Caine Understanding host adaptation and disease progression of enterovirus 71 using mouse models, reverse genetics, and in vivo imaging
TH91621B (th) วิธีการของการก่อภูมิคุ้มกันโรคเพื่อต่อต้าน 4 ซีโรไทป์ของไข้เลือดออก
TH138884A (th) วัคซีนต้านกลุ่มอาการโรคของระบบสืบพันธุ์และทางเดินหายใจในสุกรชนิดก่อโรคได้สูง (hp prrs)